Investors

Press Releases

Press Releases

October 28, 2020
REDWOOD CITY, Calif. , Oct. 28, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell related diseases, today announced the pricing of its previously announced underwritten public offering.
October 27, 2020
REDWOOD CITY, Calif. , Oct. 27, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell related diseases, today announced it intends to offer and sell, subject to market and other conditions, $250
October 21, 2020
REDWOOD CITY, Calif. , Oct. 21, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related diseases, today announced the publication of results from the multicenter, randomized, double-blind,
June 3, 2020
-- Phase 3 study in eosinophilic gastritis and/or eosinophilic duodenitis and Phase 2/3 study in eosinophilic esophagitis --  -- Top-line safety and efficacy results from both studies expected in the second half of 2021 -- REDWOOD CITY, Calif. , June 03, 2020 (GLOBE NEWSWIRE) -- Allakos Inc.
Displaying 1 - 10 of 19

Data Provided by Refinitiv. Minimum 15 minutes delayed.